Insulet Corp
NASDAQ:PODD

Watchlist Manager
Insulet Corp Logo
Insulet Corp
NASDAQ:PODD
Watchlist
Price: 273.1 USD 2.51%
Market Cap: 19.1B USD
Have any thoughts about
Insulet Corp?
Write Note

Insulet Corp
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Insulet Corp
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Insulet Corp
NASDAQ:PODD
Total Liabilities & Equity
$3B
CAGR 3-Years
15%
CAGR 5-Years
19%
CAGR 10-Years
26%
Becton Dickinson and Co
NYSE:BDX
Total Liabilities & Equity
$57.3B
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
16%
Boston Scientific Corp
NYSE:BSX
Total Liabilities & Equity
$38.1B
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
9%
Stryker Corp
NYSE:SYK
Total Liabilities & Equity
$43.8B
CAGR 3-Years
9%
CAGR 5-Years
10%
CAGR 10-Years
10%
Abbott Laboratories
NYSE:ABT
Total Liabilities & Equity
$73B
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
6%
Intuitive Surgical Inc
NASDAQ:ISRG
Total Liabilities & Equity
$17.7B
CAGR 3-Years
11%
CAGR 5-Years
14%
CAGR 10-Years
17%
No Stocks Found

Insulet Corp
Glance View

Market Cap
19.2B USD
Industry
Health Care

Insulet Corporation is a pioneering medical device company, primarily recognized for its innovative Omnipod Insulin Management System, which revolutionizes diabetes care. Founded in 2000, Insulet has focused on developing patch pump technology that offers a seamless, tubeless insulin delivery solution for individuals with insulin-dependent diabetes. This cutting-edge product allows users to manage their insulin delivery discreetly and conveniently, enhancing their quality of life and simplifying the complex regimen of diabetes management. As the prevalence of diabetes continues to rise globally, Insulet stands at the forefront of meeting a substantial medical need, capturing a significant market share with its user-friendly technology. As an investor, understanding Insulet’s growth trajectory and market potential is essential. The company has witnessed consistent revenue growth, driven by increased adoption of its Omnipod systems, and has expanded its product portfolio to include a new generation of devices that offer even greater functionality. Insulet is also heavily investing in research and development to further innovate its offerings, positioning itself competitively in the fast-evolving diabetes care market. With strong industry partnerships and a commitment to enhancing user experience, Insulet represents not just a promising investment in healthcare technology but also a company that is fundamentally improving the lives of millions.

PODD Intrinsic Value
99.02 USD
Overvaluation 64%
Intrinsic Value
Price

See Also

What is Insulet Corp's Total Liabilities & Equity?
Total Liabilities & Equity
3B USD

Based on the financial report for Sep 30, 2024, Insulet Corp's Total Liabilities & Equity amounts to 3B USD.

What is Insulet Corp's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
26%

Over the last year, the Total Liabilities & Equity growth was 23%. The average annual Total Liabilities & Equity growth rates for Insulet Corp have been 15% over the past three years , 19% over the past five years , and 26% over the past ten years .

Back to Top